Literature DB >> 7682018

The role of bradykinin in mediating ischemic brain edema in rats.

T Kamiya1, Y Katayama, F Kashiwagi, A Terashi.   

Abstract

BACKGROUND AND
PURPOSE: We investigated the hypothesis that bradykinin generation may induce ischemic brain edema in spontaneously hypertensive rats.
METHODS: Cerebral ischemia lasting 3 hours was produced by bilateral common carotid artery occlusion in 67 rats. After the ischemic period, the rats were reperfused. Cerebral water content and energy metabolites (adenosine triphosphate, lactate, and pyruvate), as well as plasma and tissue bradykinin, were measured. Additionally, using the same experimental paradigm, bradykinin synthesis inhibitors (aprotinin [n = 7] and soybean trypsin inhibitor [n = 7]) were administered immediately after ischemia induction to determine the relation of bradykinin generation to the progression of ischemic brain edema.
RESULTS: Cerebral water content increased during the 3-hour ischemic period, peaked at 30 minutes of reperfusion, and declined thereafter. Bradykinin levels in plasma and tissue rose markedly 30 minutes after reperfusion and fell thereafter. The progressive loss of adenosine triphosphate was mirrored by the rise in lactate. In the treated groups, aprotinin and soybean trypsin inhibitor administration significantly attenuated cerebral edema (p < 0.01 and p < 0.05, respectively). The treated groups also showed less lactate accumulation and more adenosine triphosphate preservation than did the controls.
CONCLUSIONS: These results demonstrate that bradykinin levels in plasma and tissue corresponded to cerebral edema progression and that bradykinin suppression decreased edema formation. These novel findings indicate that bradykinin activation augments the progression of ischemic brain edema.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7682018     DOI: 10.1161/01.str.24.4.571

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  21 in total

1.  Acute effects of bradykinin on cerebral microvascular permeability in the anaesthetized rat.

Authors:  M H Sarker; D E Hu; P A Fraser
Journal:  J Physiol       Date:  2000-10-01       Impact factor: 5.182

Review 2.  Pharmacologic strategies for combating the inflammatory response.

Authors:  Clive Landis
Journal:  J Extra Corpor Technol       Date:  2007-12

3.  Regulation of bradykinin-induced activation of volume-sensitive outwardly rectifying anion channels by Ca2+ nanodomains in mouse astrocytes.

Authors:  Tenpei Akita; Yasunobu Okada
Journal:  J Physiol       Date:  2011-06-20       Impact factor: 5.182

Review 4.  A risk-benefit assessment of aprotinin in cardiac surgical procedures.

Authors:  W B Dobkowski; J M Murkin
Journal:  Drug Saf       Date:  1998-01       Impact factor: 5.606

5.  Acute retinal ischemia inhibits endothelium-dependent nitric oxide-mediated dilation of retinal arterioles via enhanced superoxide production.

Authors:  Travis W Hein; Yi Ren; Luke B Potts; Zhaoxu Yuan; Enoch Kuo; Robert H Rosa; Lih Kuo
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-01-03       Impact factor: 4.799

6.  Tissue kallikrein protects against ischemic stroke by suppressing TLR4/NF-κB and activating Nrf2 signaling pathway in rats.

Authors:  Jiawei Yang; Jianhua Su; Fen Wan; Nan Yang; Haibo Jiang; Mingming Fang; Hang Xiao; Jun Wang; Jinrong Tang
Journal:  Exp Ther Med       Date:  2017-06-15       Impact factor: 2.447

7.  The role of bradykinin B(1) and B(2) receptors for secondary brain damage after traumatic brain injury in mice.

Authors:  Raimund Trabold; Christian Erös; Klaus Zweckberger; Jane Relton; Heike Beck; Juerg Nussberger; Werner Müller-Esterl; Michael Bader; Eric Whalley; Nikolaus Plesnila
Journal:  J Cereb Blood Flow Metab       Date:  2009-09-23       Impact factor: 6.200

8.  Development of hyperthermia following intracerebroventricular administration of endotoxin in the rat: effect of kinin B1 and B2 receptor antagonists.

Authors:  K Walker; A Dray; M Perkins
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

9.  LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces ischemic brain injury in a murine model of transient focal cerebral ischemia.

Authors:  Li Ding-Zhou; Isabelle Margaill; Bruno Palmier; Didier Pruneau; Michel Plotkine; Catherine Marchand-Verrecchia
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

10.  Evaluation of Anti-Inflammatory Effects of Helminthostachys zeylanica Extracts via Inhibiting Bradykinin-Induced MMP-9 Expression in Brain Astrocytes.

Authors:  Chuen-Mao Yang; Sien-Hung Yang; Tsong-Hai Lee; Jia-You Fang; Chwan-Fwu Lin; Mei-Jie Jou; Hsi-Lung Hsieh
Journal:  Mol Neurobiol       Date:  2015-11-02       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.